Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by made2laston May 30, 2018 11:19am

96 Views

Post# 28099191

RE:RE:We'll get to markets 3 months earlier ...

Hi All;

Today we celebrate a successful and humane treatment for cancer. What a positive event!

One star? What a sad, sick soul you have. I am a very compassionate person, but for you I will make an exception, and wish you continued misery in your sick, and twisted life.

To all others, we celebrate success;

made2last

made2last wrote: Hi bencro;

Don’t forget that with “the right to try” our system in the US, Theralase could get a head start in the market. Success stories of saved bladders could even add pressure to the FDA for rapid approval.

The best of luck to all longs;

made2last

bencro wrote: And some were talking about dilution over the last few years ... lolll .... Today's MSAB decision will bring us 3-6 months earlier to markets, once we get a FDA approval after a successful Ph. 2b. Giving the immense monthly revenues that will occur, this is a decision that will maximize shareholders value like no other decision.